lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· July 27, 2026

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

View original at finance.yahoo.com
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results OPKO Health, Inc. Conference Call to Begin Today at 4:30 p.m…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OPKO Biologics plans to advance OPK8801001 to clinical trials at the end of 2026.

    60% confidence
  • ModeX plans to enter Phase 1 studies of its in vivo CAR T platform later this year or in early 2027.

    60% confidence
  • OPKO plans to complete enrollment of the MDX2301 trial in Q3 2026, with early data presented in late 2026 or early 2027.

    60% confidence
  • OPK8801001 showed approximately 20-fold greater growth hormone receptor antagonism than established Pegvisomant therapy in vitro.

    60% confidence
  • OPKO expects to report initial safety, tolerability, pharmacokinetic and immune data for MDX2004 in the first half of 2027.

    60% confidence
  • OPKO congratulates Entera Bio on its oversubscribed $275 million private placement, which underscores the strength of its scientific platform.

    60% confidence
  • The MDX2301 trial is being funded by BARDA.

    60% confidence

Cité dans ces articles de Via News

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results: Source | Via News | fr.via.news